Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5243713 | 0.84 | ALDH1A1 (0.43) | ALDH1A1POLBSMN1; SMN2HTTHPGD | |
| SCHEMBL8159362 | 0.83 | KMT2A (0.58) | ALDH1A1POLBCYP2C19KMT2AMEN1 | |
| SCHEMBL5439162 | 0.82 | ALDH1A1 (0.58) | ALDH1A1POLBSMN1; SMN2HTTHPGD | |
| SCHEMBL6390286 | 0.81 | KMT2A (0.45) | ALDH1A1POLBSMN1; SMN2HTTHPGD | |
| SCHEMBL5288013 | 0.78 | KMT2A (0.67) | ALDH1A1POLBSMN1; SMN2HTTHPGD | |
| SCHEMBL5244144 | 0.76 | ALDH1A1 (0.40) | ALDH1A1POLBSMN1; SMN2HTTHPGD | |
| SCHEMBL5283824 | 0.75 | ALDH1A1 (0.67) | ALDH1A1POLBCYP2C19KMT2AMEN1 | |
| SCHEMBL13598933 | 0.74 | ALDH1A1 (0.66) | ALDH1A1POLBSMN1; SMN2HTTHPGD | |
| SCHEMBL4786397 | 0.72 | KMT2A (0.77) | ALDH1A1POLBKMT2AMEN1LMNA | |
| SCHEMBL2962551 | 0.72 | KMT2A (0.80) | ALDH1A1POLBKMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758873-A1 | UBIQUITIN LIGASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2007-03-07 | — | — | EP | claimed |
| WO-2006002284-A1 | UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2006-01-05 | — | — | WO | claimed |
| US-20050282818-A1 | Ubiquitin ligase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2005-12-22 | — | — | US | claimed |
| WO-2008115259-A2 | DERIVATIVES OF BENZOXADIAZOLE SUITABLE FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES | RIGEL PHARMACEUTICALS, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2006002284-A1 | UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2006-01-05 | — | — | WO | disclosed |
| US-20050282818-A1 | Ubiquitin ligase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282818-A1 | Ubiquitin ligase inhibitors | NEDD4, TRAF6, XIAP | ALDH1A1 2627/4885POLB 2997/4885SMN1; SMN2 3058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.